ClinicalTrials.gg
RecruitingNCT06369922TENSUBUpdated May 13, 2026

TENS Analgesia During Outpatient Urethral Bulking for Stress Urinary Incontinence.

An interventional study of TENS and Control TENS in Stress Incontinence Female, Urinary Incontinence and Urinary Incontinence,Stress, sponsored by University of Rochester. Recruiting at 1 site in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-13.

Primary conditionUrinary Incontinence, StressRegistry: Urinary IncontinenceReclassifiedWhy we changed it
Registry
Urinary Incontinence — the first condition term the registry derived for this study.
ClinicalTrials.gg
Urinary Incontinence, Stress
Why
  1. The study's listed conditions name Urinary Incontinence, Stress, a narrower term within Urinary Incontinence.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by University of Rochester · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 190 studies in Urinary Incontinence, Stress with a site in United States — 28 open to participants now, 41 under way, 4 of them phase 3. Urinary Incontinence, Stress · United States.

Planned enrollment
79th of 164
100 · median 99
Started
2024
with 6 others
No phase
109 of 190
18 open now
Primary completion
2027-01
later than 18 of 40 live
Registered
170th of 190
by date

Among the 190 studies in Urinary Incontinence, Stress with a site in United States, this one is the 79th largest by planned enrollment of the 164 interventional ones that give a count, is one of 7 that started in 2024, is one of 109 with no phase, reaches primary completion later than 18 of the 40 other live ones, and was the 170th registered.

Urinary Incontinence, Stress

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

Browse Urinary Incontinence, Stress studies →

Open to participants now

28 of the 190 studies in Urinary Incontinence, Stress with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 28 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 76 Urinary Incontinence, Stress studies recruiting now, 43 (57%) set no upper age limit and 18 (24%) stop at 75 or younger; 2 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 190 studies in Urinary Incontinence, Stress with a site in United States, or all of them as a file.
02

Study summary

This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing an outpatient transurethral bulking procedure for stress urinary incontinence. Subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study who currently oversee stress incontinence care. Subjects will be randomized into two groups. One group will be undergoing the cystoscopy with transcutaneous electrical nerve stimulation (TENS) for analgesia, and the second group will have the cystoscopy with placebo TENS.

Read the detailed description

This will be a double-blind randomized control trial in women with stress urinary incontinence who are undergoing outpatient transurethral bulking procedures. These subjects will be identified by the University of Rochester urologists and urogynecologists participating in the study, who oversee the patient's stress urinary incontinence management. The subjects will be asked to participate in this research project when the doctor is offering options for their SUI treatment.

Subjects will be randomized into two groups. One group will undergo transurethral bulking with TENS for analgesia, and the second group will have the procedure performed with placebo TENS. The application of the TENS device will be performed by a study team member who will know to what group the patient was randomized. Both groups will be given the VAS, satisfaction scale, and 5-point Likert scale questionnaires to be answered before, during, and after they undergo treatment on the scheduled day of the procedure.

The primary outcome will be a change in the VAS pain measurement. Investigators hypothesized that TENS used during transurethral bulking injections would result in a 10-mm decrease in VAS compared to placebo TENS.

Secondary outcomes will be:

  1. A discrete 5-point Likert Scale to assess the internal consistency of the pain rating within the study
  2. A satisfaction 10-point scale questionnaire
  3. Rate of side effects to the use of TENS (skin irritation, pain or burning at electrode site) and transurethral bulking injections (vasovagal symptoms: dizziness, nausea, vomiting, shoulder pain, vertigo, sweating, fainting),
  4. Length of procedure.
03

Conditions studied

  • Stress Incontinence Female
  • Urinary Incontinence
  • Urinary Incontinence,Stress
  • Pain
  • Pain Acute

Browse trials for

Keywords

  • TENS
  • pain
  • Transcutaneous Electrical Nerve Stimulation Analgesia
04

In context

Urinary Incontinence, Stress Reclassified

655 studies on the registry are indexed under Urinary Incontinence, Stress; 123 are open to participants now.

This study's planned enrollment of 100 is above the median of 68 across 510 interventional studies indexed under Urinary Incontinence, Stress.

Browse Urinary Incontinence, Stress studies →

Lead sponsor

University of Rochester is the lead sponsor of 729 studies on the registry; 116 are open to participants now.

Of its 56 completed or terminated interventional studies of FDA-regulated products, 44 (79%) have results posted.

Compared within Urinary Incontinence, Stress, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Urinary Incontinence. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    • Women, Age ≥18 years

      • Diagnosis of SUI
      • Scheduled to undergo transurethral bulking in the office
      • Able to read/write English

Exclusion criteria

Exclusion Criteria:

    • Cutaneous damage such as ulcers or broken skin on target treatment area

      • Currently implanted cardiac pacemaker or defibrillator
      • Pre-procedural use of opioids for pain management, less than 8 hours from last dose
      • Participants with altered sensation below the umbilicus
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Active TENS

    In the active treatment group, the TENS unit will remain on up to 30 minutes (10 minutes pre-procedure, during the procedure and during the questionnaires).

    Procedure: TENS

  • Sham comparator
    Control TENS

    The sham stimulation group will undergo the same procedure; however, the TENS stimulation current will be reduced to a minimal detectable level and turned off after 20 seconds.

    Procedure: Control TENS

Interventions

  • ProcedureTENS

    This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an "Acupuncture" mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.

  • ProcedureControl TENS

    This device will then be used for deep transcutaneous nerve stimulation at the T10-L1 and S2-S4 levels. The device will be placed and activated 5 minutes before the procedure. and the device will remain active during the procedure and will be turned off as soon as the procedure is complete (the procedure typically takes 5-15 minutes). The TENS units have pre-program settings, improving convenience, reproducibility, and reliability. Study staff will be instructed to perform TENS using an "Acupuncture" mode on the provided TENS units. The amplitude will be adjusted to a comfortable sensation that does not cause pain using adhesive electrodes. One TENS unit is able to support 4 TENS electrodes. The TENS electrodes (8 cm x 5 cm) will be placed on bilateral paraspinal muscles. The intensity of the stimulation (Hz) will be adjusted to the subjective comfort of the subject.

07

What researchers measure

Primary outcomes

  1. Mean pain measured by Visual Analog Scale (VAS)

    The VAS for pain consists of a 100-mm-long horizontal line where 0-mm equals no pain and 100-mm equals worst possible pain.

    Time frame: Before procedure

  2. Mean pain measured by Visual Analog Scale (VAS)

    The VAS for pain consists of a 100-mm-long horizontal line where 0-mm equals no pain and 100-mm equals worst possible pain.

    Time frame: Approximately 2-5 minutes into the procedure

  3. Mean pain measured by Visual Analog Scale (VAS)

    The VAS for pain consists of a 100-mm-long horizontal line where 0-mm equals no pain and 100-mm equals worst possible pain.

    Time frame: within 10 minutes after procedure

Secondary outcomes

  1. Mean pain measured by Likert scale

    A discrete, 5-point verbal Likert scale including the following options: "no pain", "minimal pain", "moderate pain", "severe pain" and "worst pain possible" will be asked to patients

    Time frame: before procedure

  2. Mean pain measured by Likert scale

    A discrete, 5-point verbal Likert scale including the following options: "no pain", "minimal pain", "moderate pain", "severe pain" and "worst pain possible" will be asked to patients

    Time frame: Approximately 2-5 minutes into the procedure

  3. Mean pain measured by Likert scale

    A discrete, 5-point verbal Likert scale including the following options: "no pain", "minimal pain", "moderate pain", "severe pain" and "worst pain possible" will be asked to patients

    Time frame: within 10 minutes after procedure

  4. Number of participants with side effects

    A check list of vasovagal symptoms will be handed to the study team member to complete if the subject reports any light headedness, nausea or sweating.

    Time frame: within 10 minutes after procedure

  5. Mean satisfaction with the procedure

    A 1-10 point satisfaction scale will be used where 10 indicates higher satisfaction.

    Time frame: within 10 minutes after procedure

  6. TENS or NO TENS

    Number of participants who guessed correctly whether they were given the active TENS or placebo TENS

    Time frame: within 10 minutes after procedure

08

Study locations

1 of 1 sites recruiting
09

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2024 (actual). Primary completion is estimated for Jan 2027, 30 months after the start.

Of 227 non-industry interventional studies with no phase under Urinary Incontinence, Stress, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 30 months is above that.

Counting every sponsor, half of 268 studies reached it within 19 months; a quarter within 9 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 12, 2024
First posted
Apr 17, 2024
StartActual
Jul 1, 2024
Primary completionEst.
Jan 31, 2027
CompletionEst.
Jun 1, 2027
Last update
May 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06369922
Responsible party
Jared Matthew Floch (Fellow, University of Rochester) — Principal investigator
First posted
Apr 17, 2024
Start date
Jul 1, 2024
Primary completion
Jan 31, 2027 (estimated)
Completion
Jun 1, 2027 (estimated)
Last update
May 13, 2026

Study contacts

Jared M Floch, DO, MS
Contact
jared_floch@urmc.rochester.edu
585-895-9301
Diego Hernandez-Aranda, MD
Contact
diego_hernandezaranda@urmc.rochester.edu
585-487-3400

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion